Skip to main content
. Author manuscript; available in PMC: 2006 Sep 1.
Published in final edited form as: Clin Cancer Res. 2005 Sep 1;11(17):6342–6351. doi: 10.1158/1078-0432.CCR-05-0596

Table 5.

Ability of the mesothelin-specific T-cell line (T35-P547-2) to lyse human tumor cell lines expressing mesothelin

% lysis (± SD)
Target Type of carcinoma HLA-A2 Mesothelin 50:1 25:1 12.5:1
CFPAC-1 Pancreatic + + 29.2 (1.3)a 26.2 (0.4)a 22.8 (0.9)a
OVCAR-3 Ovarian + + 25.9 (1.4)a 20.7 (2.2)a 14.9 (0.9)a
AsPC-1 Pancreatic − + 2.0 (0.3) 2.7 (0.3) 0.4 (0.4)
YOU Mesothelioma + + 26.0 (1.4)a 26.4 (0.3)a 17.6 (1.2)a
ROB Mesothelioma + + 51.3 (2.4)a 46.1 (0.7)a 31.2 (0.8)a
ORT Mesothelioma + + 49.4 (1.7)a 42.2 (1.7)a 31.0 (0.1)a

A 16-hour 111In release assay was performed. Results are expressed in percent specific lysis at effector-to-target ratios of 50:1, 25:1 and 12.5:1.

a

Statistical significance (P<0.01, two tailed t test) when comparing lysis of AsPC cells.